Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Date publication

janvier 2017

Journal

The New England journal of medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28002688

Résumé

An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20-expressing B cells, in the primary progressive form of the disease.

Mots clés

Adolescent, Adult, Antibodies, Monoclonal, Humanized, adverse effects, Antigens, CD20, B-Lymphocytes, immunology, Brain, diagnostic imaging, Disease Progression, Double-Blind Method, Female, Humans, Infusions, Intravenous, adverse effects, Intention to Treat Analysis, Lymphocyte Count, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis, Chronic Progressive, drug therapy, T-Lymphocytes, Young Adult

Référence

N. Engl. J. Med.. 2017 01 19;376(3):209-220